2079939-05-0
2079939-05-0
Chemical Structure
Sirpiglenastat
Synonym(s): DRP-104
- CAS No.: 2079939-05-0
- Formula:C22H27N5O5
- Molecular Weight:441.48
IUPAC Name: isopropyl (S)-2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate
InChIKey: LQNMCWOJACNQQM-PMACEKPBSA-N
SMILES: CC(C)OC([C@H](CCC(C=[N+]=[N-])=O)NC([C@@H](NC(C)=O)CC1=CNC2=CC=CC=C12)=O)=O
Biological Activity: Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sirpiglenastat | 98.77% | Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. Sirpiglenastat has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yumi Yokoyama, et al. DRP-104, a novel broad acting glutamine antagonist, induces distinctive immune modulation mechanisms and synergistic efficacy in combination with immune checkpoint blockade. J Immunother Cancer. 2019 Nov 6;7(Suppl 1):282. [Content Brief]
- [2]. Yumi Yokoyama, et al. DRP-104, a broad acting glutamine antagonist, synergizes with immune checkpoint blockade in vivo. Cancer Res 2021;81(13_Suppl):Abstract nr 1563.
